Richard M Hoffman1, Ying Shi2, Stephen J Freedland3, Nancy L Keating4, Louise C Walter5. 1. Department of Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA. Electronic address: richard-m-hoffman@uoiwa.edu. 2. San Francisco VA Medical Center, San Francisco, California, USA; Division of Geriatrics, Department of Medicine, University of California, San Francisco, California, USA. Electronic address: Ying.Shi2@va.gov. 3. Urology Division, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA. Electronic address: stephen.freedland@cshs.org. 4. Department of Health Care Policy, Harvard Medical School, and Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: keating@hcp.med.harvard.edu. 5. San Francisco VA Medical Center, San Francisco, California, USA; Division of Geriatrics, Department of Medicine, University of California, San Francisco, California, USA. Electronic address: louise.walter@ucsf.edu.
Abstract
OBJECTIVE: Concerns about over-treatment have led to practice guidelines discouraging active treatment of prostate cancer (PCa) in men with limited life expectancies and/or low-risk tumors. We evaluated treatment patterns for older veterans with localized PCa, particularly those with low-risk features. METHODS: We used VA Cancer Registry data to identify men aged 65+ diagnosed with clinically localized PCa between January 1st, 2003 and December 31st, 2008. We obtained baseline data on demographics, tumor characteristics, comorbidities, and initial treatment within 6 months of diagnosis: radical prostatectomy, radiotherapy, primary androgen-deprivation therapy (PADT), or no active treatment. National VA surveys provided facility data, including academic affiliation, availability of oncologic specialists, and distance to radiotherapy facilities. Multinomial regression analyses determined associations between patient and facility characteristics and cancer treatment for men with localized (stage<III) and low-risk PCa (stage≤IIa, PSA<10ng/mL, Gleason ≤6). RESULTS: 17,206 veterans had localized PCa, 32% age 75+, 12% had comorbidity scores ≥3, and 33% had low-risk tumors. Overall, 39% received radiotherapy, 6% surgery, 20% PADT, and 35% no active treatment. For those with low-risk cancers, older men (RR=0.36, 95% CI 0.30-0.43) and sicker men (RR=0.75, 95% CI 0.62-0.90) were less likely to receive surgery or radiotherapy versus no active treatment. Over time, more of these men received no active treatment (from 41% to 57%, P<0.001) while fewer received PADT (from 11% to 4%, P<0.001). CONCLUSION: VA treatment patterns followed evidence-based guidelines against treating older and sicker men with surgery or radiotherapy, for decreasing use of PADT, and for increasingly withholding active treatment, particularly for men with low-risk PCa. Published by Elsevier Ltd.
OBJECTIVE: Concerns about over-treatment have led to practice guidelines discouraging active treatment of prostate cancer (PCa) in men with limited life expectancies and/or low-risk tumors. We evaluated treatment patterns for older veterans with localized PCa, particularly those with low-risk features. METHODS: We used VA Cancer Registry data to identify men aged 65+ diagnosed with clinically localized PCa between January 1st, 2003 and December 31st, 2008. We obtained baseline data on demographics, tumor characteristics, comorbidities, and initial treatment within 6 months of diagnosis: radical prostatectomy, radiotherapy, primary androgen-deprivation therapy (PADT), or no active treatment. National VA surveys provided facility data, including academic affiliation, availability of oncologic specialists, and distance to radiotherapy facilities. Multinomial regression analyses determined associations between patient and facility characteristics and cancer treatment for men with localized (stage<III) and low-risk PCa (stage≤IIa, PSA<10ng/mL, Gleason ≤6). RESULTS: 17,206 veterans had localized PCa, 32% age 75+, 12% had comorbidity scores ≥3, and 33% had low-risk tumors. Overall, 39% received radiotherapy, 6% surgery, 20% PADT, and 35% no active treatment. For those with low-risk cancers, older men (RR=0.36, 95% CI 0.30-0.43) and sicker men (RR=0.75, 95% CI 0.62-0.90) were less likely to receive surgery or radiotherapy versus no active treatment. Over time, more of these men received no active treatment (from 41% to 57%, P<0.001) while fewer received PADT (from 11% to 4%, P<0.001). CONCLUSION: VA treatment patterns followed evidence-based guidelines against treating older and sicker men with surgery or radiotherapy, for decreasing use of PADT, and for increasingly withholding active treatment, particularly for men with low-risk PCa. Published by Elsevier Ltd.
Authors: J Donovan; F Hamdy; D Neal; T Peters; S Oliver; L Brindle; D Jewell; P Powell; D Gillatt; D Dedman; N Mills; M Smith; S Noble; A Lane Journal: Health Technol Assess Date: 2003 Impact factor: 4.014
Authors: Ian Thompson; James Brantley Thrasher; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Michael S Cookson; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine M Tangen Journal: J Urol Date: 2007-06 Impact factor: 7.450
Authors: James Mohler; Robert R Bahnson; Barry Boston; J Erik Busby; Anthony D'Amico; James A Eastham; Charles A Enke; Daniel George; Eric Mark Horwitz; Robert P Huben; Philip Kantoff; Mark Kawachi; Michael Kuettel; Paul H Lange; Gary Macvicar; Elizabeth R Plimack; Julio M Pow-Sang; Mack Roach; Eric Rohren; Bruce J Roth; Dennis C Shrieve; Matthew R Smith; Sandy Srinivas; Przemyslaw Twardowski; Patrick C Walsh Journal: J Natl Compr Canc Netw Date: 2010-02 Impact factor: 11.908
Authors: Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Mary Putt; Judith A Long; Chantal Montagnet; Jeffrey H Silber; Virginia W Chang; J Sanford Schwartz; Craig Evan Pollack; Yu-Ning Wong; Katrina Armstrong Journal: Med Care Res Rev Date: 2009-04-08 Impact factor: 3.929
Authors: Judd W Moul; Hongyu Wu; Leon Sun; David G McLeod; Christopher Amling; Raymond Lance; Leo Kusuda; Timothy Donahue; John Foley; Andrew Chung; Wade Sexton; Douglas Soderdahl; Norman M Rich Journal: Surgery Date: 2002-08 Impact factor: 3.982
Authors: Paolo Dell'oglio; Anne Sophie Valiquette; Sami-Ramzi Leyh-Bannurah; Zhe Tian; Vincent Trudeau; Alessandro Larcher; Shahrokh F Shariat; Umberto Capitanio; Alberto Briganti; Markus Graefen; Francesco Montorsi; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2018-03-19 Impact factor: 1.862